

PATIENT IDENTIFICATION
Known allergies / medication sensitivities:

- | | |
|--------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> NL Infusion Care, AR Gould, Presque Isle
Phone: 207-768-4589; Fax: 207-768-4183 | <input type="checkbox"/> NL Mary Dow Center, Ellsworth
Phone: 207-664-5584; Fax: 207-664-5485 |
| <input type="checkbox"/> NL Infusion Care, Blue Hill
Phone: 207-374-3995; Fax: 207-374-3970 | <input type="checkbox"/> NL Infusion Care, Mayo, Dover-Foxcroft
Phone: 207-564-4254; Fax: 207-564-4418 |
| <input type="checkbox"/> NL Infusion Care, CA Dean, Greenville
Phone: 207-695-5222; Fax: 207-695-4801 | <input type="checkbox"/> NL Mercy Cancer Care, Portland
Phone: 207-553-6868; Fax: 207-904-0917 |
| <input type="checkbox"/> NL Infusion Care, Brewer
Phone: 207-973-9785; Fax: 207-973-9788 | <input type="checkbox"/> NL Infusion Care, SVH, Pittsfield
Phone: 207-487-4052; Fax: 207-487-3995 |
| <input type="checkbox"/> NL Infusion Care, Waterville
Phone: 207-861-3380; Fax: 207-861-3348 | |

OP belimumab (Benlysta) (Paper)

Page 1 of 1

Diagnosis: Systemic Lupus Erythematosus (SLE)
 Lupus nephritis

ICD10: _____

Verification of T SPOT or Quantiferon: TB testing is required prior to initiation of therapy, a change in living environment, or travel to an area that would pose an increased risk of TB. Please indicate date and result of test done:

T SPOT: Date: ____/____/____ Result: _____

Quantiferon TB Gold Test: Date: ____/____/____ Result: _____

Hepatitis B and C Testing:

Hepatitis B: Date: ____/____/____ Result: _____

Hepatitis C: Date: ____/____/____ Result: _____

IV Access:

- Saline Lock:
 - Insert peripheral Saline Lock; *may leave in for consecutive treatment days*
 - Discontinue Saline Lock after therapy completed
- PICC Line:
 - Routine PICC Line Care, labs and restoration
 - Discontinue PICC Line (verify regimen is complete with provider prior to removing line)
- Porta cath / Central Access Device (Hickman, Triple lumen):
 - Porta cath access, labs, restoration and de-access / Central Access Device use and care

Height: _____ cm **Weight:** _____ kg

Premedication:

- Acetaminophen (Tylenol) 650 mg, PO, ONCE
- Cetirizine (Zyrtec) 10 mg, PO, ONCE
- methylPREDNISolone 40 mg, Soln, IVP, ONCE
- methylPREDNISolone 125 mg, Soln, IVP, ONCE
- methylPREDNISolone _____ mg, Soln, IVP, ONCE

Medication:

- belimumab (Benlysta) 10 mg/kg, IVPB, ONCE every 2 weeks for 3 doses, then ONCE every 4 week interval, Infuse over 1 hour
- belimumab (Benlysta) 10 mg/kg, IVPB, ONCE every 4 weeks, Infuse over 1 hour

Duration: 6 months 1 year
 Other: _____

Other: _____



100000067

Date: _____ Time: _____
 Provider Signature: _____ Print Name: _____
 Phone: _____ Fax: _____
 Pharmacy Signature: _____

PROVIDERS MUST EXERCISE INDEPENDENT CLINICAL JUDGMENT WHEN USING ORDER SETS
 June 2024 (Header updated and removed reference to Policies)